Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Melanoma
Melanoma News & Features
Depth of Response to TKIs, Immunotherapies Correlates to Longer PFS and OS
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Secondary end points were not significantly different between the 2 groups, including overall survival.
Melanoma Clinical Trials
Clinical Trial: Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Clinical Trial: Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)
Clinical Trial: Study of Families With Melanoma
Clinical Trial: Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Clinical Trial: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Want to read more?
Please login or register first to view this content.
Next post in Melanoma
